CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kyn Therapeutics, a biotechnology company advancing new immunometabolism therapies for treating cancer, today announced the appointments of Ronald Renaud as chairman of its board of directors and Francisco Quintana, Ph.D., as a new member of Kyn’s scientific advisory board.
“The Kyn team is delighted to welcome Ron as our new chairman. His diverse corporate leadership experience will add significant value to our oversight as we transition to a clinical-stage company and advance our differentiated development programs in immunometabolism,” said Mark Manfredi, Ph.D., president and chief executive officer of Kyn Therapeutics. “We also welcome the insights of Dr. Quintana, whose expertise in key areas relating to our programs will inform both our preclinical activities and clinical strategy.”
Mr. Renaud currently serves as the chief executive officer of Translate Bio. Formerly, he served as president and chief executive officer at Idenix Pharmaceuticals until its acquisition by Merck in August 2014. Prior to that, Mr. Renaud served in several key roles at Idenix including chief financial officer and chief business officer. Before joining Idenix, he served as senior vice president and chief financial officer of Keryx Biopharmaceuticals, following a career as a biotechnology equity research analyst at several major investment firms. Mr. Renaud also serves on the board of directors for Chimerix Inc., Axial BioTherapeutics and Akebia Therapeutics.
“Immunometabolism is a fascinating new frontier of immuno-oncology, and Kyn has assembled a pipeline that approaches compelling pathways from unique angles,” said Mr. Renaud. “There is a major need for therapeutics that improve the clinical outcomes of cancer immunotherapies, so I am pleased to join a team that has connected novel science with patient need so clearly.”
Dr. Quintana is a highly-awarded immunologist and has published over 140 peer-reviewed articles and book chapters. He is the recipient of multiple awards including the Lady Anne Chain Prize for Academic Excellence and Scientific Achievements, the Award for Outstanding Research Achievement from Nature Biotechnology, and the Mentor Award from Harvard Medical School. He earned his Ph.D. from the Weizmann Institute of Science and completed postdoctoral training at the Weizmann Institute of Science and at Brigham and Women’s Hospital, Harvard Medical School.
About Kyn Therapeutics
Kyn Therapeutics is a biotechnology company advancing new immunometabolic therapies for cancer. A growing body of research indicates that key metabolites can exert broad suppressive or enhancing effects on the immune system through a complex network of cellular interactions, providing targets for new therapies that could significantly enhance patient response rates to checkpoint inhibitors. Kyn Therapeutics is advancing three development programs with targets strongly implicated in immunosuppression across a range of tumor types and via multiple immune cell effects. Kyn Therapeutics is based in Cambridge, Massachusetts. For more information, visit www.kyntherapeutics.com. Follow us on Twitter and LinkedIn.